SCHEMBL4146183

SCHEMBL4146183

C=Cc1ccc(-c2ccc3nccc(N)c3c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 2/20 0.50
NCF1 P14598 1/20 0.43
MAP4K4 O95819 9/20 0.42
PIK3CG P48736 2/20 0.41
PIK3CA P42336 2/20 0.40
PIK3CD O00329 1/20 0.40
ABL1 P00519 1/20 0.40
EGFR P00533 1/20 0.40
HCK P08631 1/20 0.40
SRC P12931 1/20 0.40
KDR P35968 1/20 0.40
PIK3CB P42338 1/20 0.40
MTOR P42345 1/20 0.40
EPHB4 P54760 1/20 0.40
PRKDC P78527 1/20 0.40
SOS2 Q07890 1/20 0.39
HDAC2 Q92769 1/20 0.37
MAPKAPK2 P49137 1/20 0.37
RAF1 P04049 1/20 0.36
BRAF P15056 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29061683 0.80 MAP4K4 (0.60) NR4A2NCF1MAP4K4PIK3CGPIK3CA
SCHEMBL4151090 0.80 MAP4K4 (0.60) NR4A2NCF1MAP4K4PIK3CGPIK3CA
SCHEMBL4155195 0.75 NR4A2 (0.54) NR4A2NCF1MAP4K4PIK3CGPIK3CA
SCHEMBL6201297 0.73 NR4A2 (0.56) NR4A2NCF1PIK3CGPIK3CAPIK3CD
SCHEMBL5758549 0.73 NR4A2 (0.56) NR4A2NCF1MAP4K4PIK3CGPIK3CA
SCHEMBL4139488 0.71 NR4A2 (0.49) NR4A2NCF1MAP4K4PIK3CGPIK3CA
SCHEMBL29725526 0.71 ACVR1 (0.56) NR4A2NCF1PIK3CA
SCHEMBL4153922 0.71 NR4A2 (0.53) NR4A2NCF1MAP4K4PIK3CGPIK3CA
SCHEMBL24150187 0.70 PLCG1 (0.56) MAP4K4PIK3CDEGFRSRCMTOR
SCHEMBL30210360 0.70 NR4A2 (0.66) NR4A2NCF1PIK3CGPIK3CAPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069338-A1 Method for predicting skin sensitizing activity of compounds DICKSON JR JOHN K 2009-03-12 US disclosed
US-7452887-B2 Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof AMPHORA DISCOVERY CORPORATION (US) 2008-11-18 US disclosed
US-20060009460-A1 Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof AGRIUS GROUP, LLC. 2006-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069338-A1 Method for predicting skin sensitizing activity of compounds ATP5ME, ABCG2, ATP5MG NR4A2 1882/4885NCF1 672/4885MAP4K4 1842/4885
US-20060009460-A1 Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof ATP5ME, ATP5MG, ATP5MK NR4A2 3517/4885NCF1 2180/4885MAP4K4 1968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.